HEPTAMINOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C8H19NO
Molecular Weight	145.2426
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(N)CCCC(C)(C)O

InChI

InChIKey=LREQLEBVOXIEOM-UHFFFAOYSA-N

InChI=1S/C8H19NO/c1-7(9)5-4-6-8(2,3)10/h7,10H,4-6,9H2,1-3H3

HIDE SMILES / InChI

Description
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014397.pdf | https://www.ncbi.nlm.nih.gov/pubmed/1929117 | https://www.ncbi.nlm.nih.gov/mesh/68006535

Heptaminol is an amino alcohol that has been used as a myocardial stimulant and vasodilator and to relieve bronchospasm. Its most common therapeutic use is in orthostatic hypotension. The mechanism of heptaminol's therapeutic actions is not well understood although it has been suggested to affect catecholamine release or calcium metabolism.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Voltage-dependent L-type calcium channel subunit alpha-1C 4 Target ID: CHEMBL2366456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22761000	Inhibitor 8297	15.3 µM [IC50]
norepinephrine uptake 18 Target ID: GO:0051620 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2386550	Inhibitor 8297	60.0 µM [Ki]
catecholamine uptake 2 Target ID: GO:0090493 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2386550	Inhibitor 8297	650.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypotension 28 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014397.pdf https://www.tabletwise.com/medicine/heptaminol	Primary		Approved 8429	Corasore Approved Use Is for the treatment of hypotension, fainting tendency and slight to moderately severe circulatory collapse; Asthenia, nervous and physical fatigue in general and sporting medicine; Adjuvant treatment of mild and moderate cases of heart failure particularly incipient pulmonary edema; Heart failure associated with toxic, infectious, degenerative orarteriosclerotic myocardial disease; Neonatal asphyxia.

PubMed

Title	Date	PubMed
Metabolism of isometheptene in human urine and analysis by gas chromatography-mass spectrometry in doping control.	2005 Dec 5	16242387

Patents

Sample Use Guides

In Vivo Use Guide

Infants & children under 12 years: 4-16 drops (25 -100 mg) depending on age, 2 – 4 times daily, up to 6 times daily if necessary, or as directed by the physician. Adults & children over 12 years: One tablet or 25 drops, (150 mg) 2-4 times daily, up to 6 times daily.

Route of Administration: Oral

In Vitro Use Guide

1. The effects of heptaminol on calcium current amplitude and characteristics were studied in single ventricular myocytes of guinea-pig by use of the whole cell configuration of the patch clamp technique. 2. A concentration-dependent decrease in ICa amplitude was observed. At heptaminol concentration as low as 10(-6) M, this effect was observed in only two cells (n = 6). At 10(-5) M the reduction of ICa was of 30 +/- 15% (n = 11). Both at -40 mV and -80 mV HP, heptaminol (10(-5) M) significantly increased the steady state inactivation of ICa.

Name

Type

Language

HEPTAMINOL

Official Name

English

heptaminol [INN]

Common Name

English

6-AMINO-2-METHYL-2-HEPTANOL

Systematic Name

English

2-AMINO-6-HYDROXY-6-METHYLHEPTANE

Systematic Name

English

6-HYDROXY-6-METHYL-2-AMINOHEPTANE

Systematic Name

English

(5-HYDROXY-1,5-DIMETHYLHEXYL)AMINE

Systematic Name

English

GINKOR

Brand Name

English

6-METHYL-2-AMINO-6-HEPTANOL

Systematic Name

English

2-METHYL-6-AMINO-2-HEPTANOL

Systematic Name

English

6-HYDROXY-6-METHYL-2-HEPTAMINE

Common Name

English

Heptaminol [WHO-DD]

Common Name

English

6-HYDROXY-6-METHYL-2-HEPTYLAMINE

Systematic Name

English

HEPTAMINOL [MI]

Common Name

English

2-HEPTANOL, 6-AMINO-2-METHYL-

Systematic Name

English

CORASORE

Brand Name

English

Classification Tree Code System Code

WHO-ATC

C01DX08